RxDoctor Payments Data

Christopher Hughes, MD

Pulmonary Disease · Saint Clair Shores, MINPI 1194740936

Payments from drug & device makers

$799in general payments, 2019–2025

Across 50 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$263
  • AstraZeneca$165
  • Boehringer Ingelheim$76
  • Sunovion Pharmaceuticals Inc.$71
  • Actelion Pharmaceuticals US, Inc.$45
  • Philips North America LLC$35
  • plus $144 from 8 others

What the payments were for

  • Food & beverage$799100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$799 in reported general payments places this provider in the 40th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$176,700
Medicare patients
409
Services billed
1,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter586$559,003
Breztri AerosphereBudesonide/Glycopyr/Formoterol67$58,729
Breo ElliptaFluticasone/Vilanterol97$52,877
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr68$42,835
Incruse ElliptaUmeclidinium Bromide53$24,907
SymbicortBudesonide/Formoterol Fumarate75$23,261
Albuterol Sulfate HfaAlbuterol Sulfate352$16,092
Spiriva RespimatTiotropium Bromide22$15,048
Spiriva HandihalerTiotropium Bromide22$11,639
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate50$11,099
Fluticasone-SalmeterolFluticasone Propion/Salmeterol52$10,814
Advair HfaFluticasone Propion/Salmeterol24$10,795
Ventolin HfaAlbuterol Sulfate97$9,007
DuleraMometasone/Formoterol15$6,137
Wixela InhubFluticasone Propion/Salmeterol27$5,946

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$263$685,499820 claims
AstraZenecaBreztri Aerosphere, Symbicort$165$81,989142 claims
Boehringer IngelheimSpiriva Respimat$76$15,04822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Saint Clair Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →